ECOG-ACRIN honored 46 member networks and programs for outstanding achievement in accrual, scientific contribution, & administrative participation in 2023. See the academic cancer centers, networks, community-based programs & principal investigators here: https://t.co/IK43N3WYHY
In phase 2 #ClinicalTrial EA1211/DIRECT, researchers are using an #imaging test called a FDG-PET/CT scan to try to better predict response to therapy for patients with #HER2positive#BreastCancer. Learn more: https://t.co/JdsOLY4xf8
EA1211/DIRECT aims to help doctors make better (more personalized) decisions around treatment for #patients with #HER2positive#BreastCancer. Consider learning more about this phase 2 #clinicaltrial if you have HER2-positive breast cancer. For more info: https://t.co/JdsOLY3ZpA
The DAISY trial of T-DXd in MBC with variable HER2 expression is out on @NatureMedicine. Many important findings, including a similar ORR with T-DXd in HER2-low (37.5%) & HER2-0 (29.7%) MBC. Congrats to @FerMosele@FAndreMD et al for this impressive work! https://t.co/dIqTdLn78M
Researchers are testing an alternative approach to standard imaging to measure treatment response in patients w/ metastatic #breastcancer that has spread to the bones. FEATURE (the EA1183 trial) is led by @drjenspecht of @SeattleCCA @UWMedicine. For more: https://t.co/gaBp9MlVQK
If you have #breastcancer that has spread to the bones, you may be eligible for the FEATURE clinical trial, where researchers are studying if imaging with FDG-PET/CT is better than a standard bone scan to assess treatment response. Learn more: https://t.co/gaBp9MmtGi #BCSM
Researchers are testing an alternative approach to standard imaging to measure treatment response in patients w/ metastatic #breastcancer that has spread to the bones. FEATURE (the EA1183 trial) is led by @drjenspecht of @SeattleCCA @UWMedicine. For more: https://t.co/gaBp9MlVQK